Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.6952W HIGH $22.55
Volume
245.66 K
Value Traded
1.84 M
Short % Float
7.4%
+2.46%Week
+2.92%1 Month
-1.36%3 Month
+3.88%6 Month
-78.02%5 Year
-46.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
230.79 M
EPS (TTM)
-4.19
P/E Ratio
-
Ent. Value
-26.82 M
Total Shares
19.83 M
Float Shares
18.15 M
Insiders
8.45%
Institutions
92.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KROS Catalyst Timeline
Dated clinical, regulatory and corporate events for Keros Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Keros Therapeutics, Inc.
363Total events
6Upcoming
51Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedrinvaterceptTrial
First patient dosed in Phase 2 trial of rinvatercept in DMD
Duchenne muscular dystrophy (DMD)source ↗
▲Milestone PaymentelriterceptCorporate
Received $20 million development milestone payment from Takeda under elritercept license agreement
▲First Patient DosedelriterceptTrial
First patient dosed in ELRiSE MDS clinical trial
myelodysplastic syndromessource ↗
▲Milestone PaymentelriterceptCorporate
Keros expects $20 million development milestone payment from Takeda following first patient dosed in ELRiSE MF
myelofibrosissource ↗
▲Trial InitiationrinvaterceptTrial
Phase 2 clinical trial initiated for rinvatercept in DMD
Duchenne muscular dystrophysource ↗
▲First Patient DosedelriterceptTrial
First patient dosed in ELRiSE MDS Phase 3 trial of elritercept
myelodysplastic syndromessource ↗
▲Milestone PaymentelriterceptCorporate
Keros to receive $20 million development milestone payment from Takeda
myelodysplastic syndromessource ↗
◆Oral PresentationPresentation
Participation at Goldman Sachs 47th Annual Global Healthcare Conference
▲Partnership / LicenserinvaterceptCorporate
Collaboration with MGH for Phase 2 trial design in ALS MyMatch program
amyotrophic lateral sclerosissource ↗
◆Oral PresentationrinvaterceptPresentation
Presented additional data from Phase 1 trial of rinvatercept at 2026 MDA Clinical & Scientific Conference
neuromuscular diseasessource ↗
◆Poster PresentationrinvaterceptPresentation
Preclinical presentation: KER-065 Improved Muscle and Bone Mass and Strength in D2.mdx Mouse Model of DMD
Duchenne muscular dystrophysource ↗
◆Trial InitiationKER-065Trial
Phase 2 clinical trial start for KER-065 in DMD
Duchenne muscular dystrophysource ↗
▼Equity OfferingCorporate
Final results of cash tender offer to repurchase up to 10,950,165 shares at $17.75 per share
▼Equity OfferingCorporate
Preliminary results of cash tender offer to repurchase up to 10,950,165 shares at $17.75 per share
▼Equity OfferingCorporate
Commences issuer tender offer to repurchase up to $194.4 million shares at $17.75 per share
◆Oral PresentationKER-065Presentation
Presented additional clinical data from Phase 1 trial of KER-065 at ASBMR 2025
Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Orphan Drug DesignationKER-065Designation
FDA granted Orphan Drug designation for KER-065 for DMD
Duchenne muscular dystrophysource ↗
▼Program DiscontinuationciboterceptDiscontinuedCorporate
Discontinuation of all material internal development activities for cibotercept
▲Topline ReadoutKER-065Clinical Data
Initial topline results from Phase 1 trial of KER-065 in healthy volunteers
healthy volunteerssource ↗
▲First Patient DosedelriterceptTrial
First patient dosed in Phase 3 RENEW trial of elritercept in MDS
transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromessource ↗
▲Milestone PaymentelriterceptCorporate
$10 million milestone payment triggered by first patient dosing in RENEW trial
◆Timing GuidancePresentation
Upcoming clinical data updates from three clinical assets expected over next nine months
◆Oral PresentationPresentation
Participation at Goldman Sachs 46th Annual Global Healthcare Conference
◆Quarterly UpdateCorporate
Company announced return of $375 million excess capital to stockholders
▼Program DiscontinuationciboterceptDiscontinuedCorporate
Discontinuation of cibotercept development in PAH after TROPOS Phase 2 trial analysis
pulmonary arterial hypertensionsource ↗
▼Topline ReadoutciboterceptDiscontinuedClinical Data
Topline data from TROPOS trial announced
pulmonary arterial hypertensionsource ↗
▼Restructuring LayoffsCorporate
Corporate restructuring reducing headcount by approximately 45%
▲Topline ReadoutKER-065Clinical Data
Initial topline results from Phase 1 trial of KER-065 in healthy volunteers
neuromuscular diseasessource ↗
◆Oral PresentationPresentation
Participation at Bank of America 2025 Global Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How KROS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | KER-047 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$47M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 63%
Micro Cap(rank 415 of 658)
Percentile Rank
Keros Therapeutics, Inc. faces pipeline headwinds (32/100), with $187M risk-adjusted pipeline value, led by KER-065 in Duchenne Muscular Dystrophy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KER-065 Small moleculeNCT07704099 | Duchenne Muscular Dystrophy | Phase 2 | RECRUITING | 36 | Sep 23, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every KROS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rinvatercept | neuromuscular diseases, specifically Duchenne muscular dystrophy and amyotrophic lateral sclerosis | Phase 1 | 2026-03-09 | increase in muscle mass; decrease in fat mass; increase in bone mineral densityRead More | Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tanini AnnitaOfficer (Corp. Controller & VP, Finance) | Sell | -1,224 45,144 held | $10.29 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KROS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.2 % | 8.12 M | 759.15 K |
KROS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KROS ranks across every disease it competes in
Competitive Position is a premium feature
See how KROS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKROS News
KROSKeros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Keros Therapeutics announced it will receive a $20 million milestone payment from Takeda following the first patient dosing in the Phase 3 ELRiSE MF clinical trial. This trial aims to assess the efficacy and safety of elritercept in patients with myelofibrosis and anemia. Keros has a global license agreement with Takeda, which could yield over $1.1 billion in milestone payments.
Read more →KROSKeros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics has announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for Duchenne muscular dystrophy (DMD). This trial aims to assess the safety and efficacy of rinvatercept, which is designed to enhance muscle and bone health. The initiative reflects Keros's commitment to addressing the significant treatment gaps in DMD.
Read more →KROSKeros Therapeutics Announces $5 Million Share Repurchase Authorization
Keros Therapeutics has announced a $5 million share repurchase program after receiving a $20 million milestone payment from Takeda Pharmaceuticals. This payment follows the dosing of the first patient in the ELRiSE MDS clinical trial. The repurchase program allows management to buy back shares depending on market conditions and other factors.
Read more →KROSKeros Therapeutics Reports Second Quarter 2026 Financial Results
Keros Therapeutics reported its Q2 2026 financial results, highlighting the initiation of a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy. The company noted a reduced net loss compared to the previous year, attributed to decreased R&D expenses following corporate restructuring. Keros anticipates presenting initial trial data in early 2027 and expects sufficient cash reserves to support operations until mid-2028.
Read more →KROSKeros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Keros Therapeutics announced a $20 million milestone payment from Takeda following the first patient dosing in the ELRiSE MDS clinical trial. This Phase 3 trial aims to evaluate elritercept against epoetin alfa for treating anemia in myelodysplastic syndromes. Keros is also eligible for additional milestone payments exceeding $1.1 billion and plans to distribute part of the proceeds to shareholders.
Read more →KROS▲ +5.6%on this news
Keros Therapeutics Appoints Anne Prener to its Board of Directors
Keros Therapeutics has appointed Dr. Anne Prener to its Board of Directors, effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience, which Keros believes will support its corporate strategy and long-term growth. The company aims to address significant unmet patient needs through its innovative therapeutics.
Read more →KROSKeros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Keros Therapeutics announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 8, 2026. CEO Jasbir S. Seehra will present in a fireside chat format. The event will be accessible via a live audio webcast and archived replay on Keros' website. Keros is focused on developing therapeutics targeting TGF-β signaling disorders.
Read more →KROS▼ -8.3%on this news
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported its financial results for Q1 2026, showing a net loss of $23.7 million compared to a net income of $148.5 million in Q1 2025. The decrease was attributed to reduced revenue from a license agreement with Takeda and lower R&D expenses due to corporate restructuring. Keros is optimistic about advancing its pipeline, particularly with elritercept entering Phase 3 trials for myelofibrosis-related anemia.
Read more →KROSKeros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Keros Therapeutics has partnered with the Sean M. Healey & AMG Center for ALS to design a Phase 2 clinical trial for rinvatercept, targeting patients with ALS. This collaboration is part of the ALS MyMatch program, which utilizes biomarker-driven approaches to match patients with experimental therapies. The initiative aims to enhance treatment options for ALS, a progressive disorder with significant unmet needs.
Read more →KROSKeros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics presented additional data from its Phase 1 trial of rinvatercept at the 2026 MDA Conference. The data highlighted the drug's potential in treating neuromuscular diseases like Duchenne muscular dystrophy and amyotrophic lateral sclerosis. The trial showed that rinvatercept was well-tolerated, with significant improvements in muscle mass and bone density. Keros plans to advance rinvatercept into Phase 2 trials.
Read more →KROS▼ -15%on this newsshared move
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics reported its financial results for Q4 and full year 2025, highlighting a net income of $87 million and a reduced net loss compared to the previous year. The company is focusing on advancing its lead product, rinvatercept, into Phase 2 trials for Duchenne muscular dystrophy and engaging regulators for trials in ALS. Despite financial progress, there are concerns regarding increased expenses and a decrease in cash reserves.
Read more →KROSKeros Therapeutics Appoints Charles Newton to its Board of Directors
Keros Therapeutics has appointed Charles Newton to its Board of Directors, effective March 9, 2026. Newton brings substantial expertise in healthcare finance, having held senior roles at several investment banks and biotech companies. His addition is expected to complement the existing skillset of Keros' board, aiding in the advancement of their clinical programs and strategic initiatives. Concurrently, Carl Gordon will step down from the board on the same date, marking a transition in Keros' leadership team.
Read more →KROSKeros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics has announced its participation in several healthcare conferences where its President and CEO, Jasbir S. Seehra, Ph.D., will present. The events include the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference, scheduled for late February and early March 2026, respectively. Archived presentations will be available on the company's website for 90 days after the events. This engagement highlights Keros' focus on developing treatments for disorders related to the transforming growth factor-beta family of proteins.
Read more →KROSKeros Therapeutics Announces Final Results of Tender Offer
Keros Therapeutics announced the final results of its cash tender offer, successfully repurchasing 10,950,165 shares at $17.75 each, totaling approximately $194.4 million. The offer concluded on November 18, 2025, and was part of a broader $375 million capital return initiative. A total of 17,712,262 shares were tendered, leading to a pro rata acceptance rate of about 62.30%. The company will utilize its existing cash for the purchases.
Read more →KROSKeros Therapeutics Announces Preliminary Results of Tender Offer
Keros Therapeutics announced preliminary results of its cash tender offer for up to 10,950,165 shares at $17.75 each, concluding its $375 million capital return program. Approximately 16,659,732 shares were tendered, exceeding the amount Keros intends to repurchase, leading to a pro-rata acceptance of shares. The final number of shares purchased will be confirmed after the guaranteed delivery period. Keros aims to return payment to shareholders promptly following the completion of the transaction.
Read more →KROSKeros Therapeutics Reports Third Quarter 2025 Financial Results
Keros Therapeutics reported its financial results for Q3 2025, highlighting a net loss of $7.3 million, significantly improved from $53.0 million in Q3 2024. The company is advancing its candidate elritercept into a Phase 3 trial for myelodysplastic syndromes, while also preparing for a Phase 2 trial of KER-065 for Duchenne muscular dystrophy. Keros maintains a strong cash position of $693.5 million, expected to fund operations into 2028.
Read more →KROS▲ +9.8%on this news
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
Keros Therapeutics has launched a cash tender offer to repurchase up to $194.4 million of its common stock as part of a broader $375 million capital return initiative. The offer, priced at $17.75 per share, will expire on November 18, 2025, unless extended. Shareholders are advised to consider their options carefully and consult with advisors before participating.
Read more →KROSKeros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Keros Therapeutics has announced a plan to return $375 million in excess capital, including a tender offer to repurchase shares worth $194 million. The company will repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital at $17.75 per share. Additionally, Keros plans to distribute a portion of future proceeds from its agreement with Takeda Pharmaceuticals to stockholders. The company aims to start a Phase 2 trial for KER-065 in early 2026.
Read more →KROSKeros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Keros Therapeutics presented additional clinical data for KER-065 at the ASBMR 2025 Annual Meeting. The Phase 1 trial demonstrated that KER-065 was well-tolerated among healthy male volunteers, with no serious adverse events reported. The data highlights KER-065's potential in treating Duchenne muscular dystrophy and its effects on bone health.
Read more →About Keros Therapeutics, Inc.
Headquarters1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
BIOPHARMAWATCH ELITE PLUS
Trade the next KROS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime